505(b)(2) Products
Total Trials
1
As Lead Sponsor
0
As Collaborator
Total Enrollment
21
NCT06065462
Safety and Efficacy of Targeting PP2A in Ovarian Clear Cell Carcinoma Using Dostarlimab and LB-100
Phase: Phase 1/2
Role: Collaborator
Start: Nov 10, 2023
Completion: Jan 31, 2026
Loading map...